Sophia Genetics Partners with Synnovis for Liquid Biopsy Testing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 13 2026
0mins
Sophia Genetics announced a partnership with Synnovis, one of England's pathology providers, to bring liquid biopsy testing to lung and breast cancer patients across the U.K. as part of NHS England's "revolutionary blood test-first" program. The new blood-based test offered by Synnovis can help fast-track cancer patients to receive targeted therapy up to two weeks earlier, while helping some avoid further tests and invasive treatments such as chemotherapy. Synnovis and Sophia Genetics anticipate that the application will be used to test approximately 7,000 breast and lung cancer patients annually, or roughly one third of all ctDNA tests in England, as the demand for liquid biopsy testing increases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SOPH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SOPH
Wall Street analysts forecast SOPH stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.080
Low
7.00
Averages
7.00
High
7.00
Current: 5.080
Low
7.00
Averages
7.00
High
7.00
About SOPH
SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SOPHiA GENETICS Partners with Synnovis to Advance Liquid Biopsy Testing
- Launch of Liquid Biopsy Testing: SOPHiA GENETICS partners with leading UK pathology provider Synnovis to introduce the MSK-ACCESS® liquid biopsy test as part of NHS's 'blood test-first' initiative, aiming to serve approximately 7,000 lung and breast cancer patients annually.
- Accelerated Treatment Plans: The test detects actionable genomic alterations from a single blood draw, enabling cancer patients to receive targeted therapy up to two weeks earlier, thereby reducing the need for further testing and invasive treatments, which enhances patient care efficiency.
- Real-World Impact: Synnovis supports around 400 patients monthly with ctDNA liquid biopsy testing, with successful cases demonstrating that patients can receive personalized treatment plans within two weeks, showcasing the practical effectiveness and potential clinical value of this advanced care.
- Strategic Significance: This collaboration enhances NHS's genomic testing infrastructure and introduces additional indications for future cancer screening programs, marking a pivotal moment for the scalable application of liquid biopsy in the UK and promoting accessibility in precision oncology.
See More
SOPHiA GENETICS Partners with Synnovis for Liquid Biopsy Testing in the UK
- Launch of Liquid Biopsy Testing: SOPHiA GENETICS has partnered with Synnovis to introduce the MSK-ACCESS® liquid biopsy test as part of NHS's 'blood test-first' initiative, aiming to serve approximately 7,000 lung and breast cancer patients annually.
- Accelerated Treatment Plans: This test detects actionable genomic alterations from a single blood draw, enabling cancer patients to receive targeted therapy up to two weeks earlier, thereby reducing the need for invasive treatments like chemotherapy and enhancing patient care.
- Real-World Impact: Following a successful pilot, Synnovis is currently supporting around 400 patients per month with ctDNA liquid biopsy testing, demonstrating the effectiveness of this technology in real-world healthcare settings and facilitating rapid personalized treatment plans for patients.
- Strategic Implications: This collaboration not only showcases SOPHiA GENETICS' AI-driven analytical capabilities but also provides NHS with a scalable liquid biopsy solution, marking a significant advancement in the widespread application of precision oncology in the UK, which is expected to greatly improve cancer treatment outcomes.
See More
SOPHiA Genetics Reports Q1 2025 Earnings Results
- Earnings Highlights: SOPHiA Genetics reported a Q1 2025 GAAP EPS of -$0.27, indicating a loss; however, revenue increased to $21.7 million, reflecting a 21.9% year-over-year growth, showcasing the company's ongoing potential in the genomics sector.
- Guidance Reaffirmation: The company reaffirmed its FY 2025 revenue guidance, projecting revenues between $92 million and $94 million, representing approximately 20% to 22% year-over-year growth, indicating strong confidence in future performance and positive market demand.
- Market Performance: Despite the reported loss, SOPHiA Genetics' revenue growth highlights its competitiveness in the genomics market, particularly as precision medicine and personalized treatment gain traction, potentially attracting more investor interest.
- Strategic Outlook: The company continues to invest in R&D and market expansion, aiming to enhance market share through innovative technologies and product offerings, thereby achieving sustainable growth and solidifying its leadership position in the industry.
See More
SOPHiA GENETICS Reports Strong Q1 Results with 22% Revenue Growth
- Significant Revenue Growth: SOPHiA GENETICS achieved a 22% year-over-year revenue growth in Q1 2026, reaching $21.688 million, reflecting strong market demand for its precision medicine capabilities, particularly as U.S. hospitals and laboratories increasingly seek AI-driven solutions.
- Record Genomic Analyses: The company completed 108,000 genomic analyses in the first quarter, setting a new record that indicates the broad application of its platform and the continued expansion of its customer base, further solidifying its market position in new applications like Liquid Biopsy and BioPharma partnerships.
- Strong Future Growth Momentum: CEO Jurgi Camblong highlighted that with the launch of new applications and expansion in the U.S. market, the business momentum remains robust, which will serve as a major catalyst for future growth and enhance the company's operational leverage.
- Transparency in Non-IFRS Reporting: The company emphasizes the use of non-IFRS measures in its financial reporting to provide investors with a clearer understanding of its operational performance, acknowledging the limitations of these metrics while still offering valuable insights into the company's future financial health.
See More
SOPHiA GENETICS Partners with Mount Sinai to Advance Cancer Research
- Collaboration Enhances Cancer Research: SOPHiA GENETICS announced a partnership with Mount Sinai Health System to adopt the AI-driven SOPHiA DDM™ platform, aimed at advancing cancer research and genomic testing capabilities, supporting care for over 4,000 oncology patients annually.
- Efficiency Optimization through Technology Integration: Mount Sinai's Molecular Pathology team will leverage SOPHiA DDM™ to enhance next-generation sequencing capabilities for blood cancers and solid tumors, significantly reducing manual interpretation time by consolidating critical steps in the analysis pipeline, thereby improving operational efficiency.
- Global Network Expansion: Mount Sinai joins a network of over 990 global institutions utilizing SOPHiA DDM™ to accelerate precision medicine, reflecting SOPHiA GENETICS' mission to democratize data-driven medicine and improve patient outcomes worldwide.
- Commitment to Scientific Innovation: The Director of Molecular Oncology Pathology at Mount Sinai stated that this collaboration reinforces the hospital's commitment to scientific innovation by integrating powerful digital tools into workflows, supporting high-quality, data-driven cancer care, and enhancing testing turnaround times to improve patient care quality.
See More
SOPHiA GENETICS (SOPH) Q4 2025 Earnings Transcript
See More
SOPHiA GENETICS Partners with Synnovis to Advance Liquid Biopsy Testing
- Launch of Liquid Biopsy Testing: SOPHiA GENETICS partners with leading UK pathology provider Synnovis to introduce the MSK-ACCESS® liquid biopsy test as part of NHS's 'blood test-first' initiative, aiming to serve approximately 7,000 lung and breast cancer patients annually.
- Accelerated Treatment Plans: The test detects actionable genomic alterations from a single blood draw, enabling cancer patients to receive targeted therapy up to two weeks earlier, thereby reducing the need for further testing and invasive treatments, which enhances patient care efficiency.
- Real-World Impact: Synnovis supports around 400 patients monthly with ctDNA liquid biopsy testing, with successful cases demonstrating that patients can receive personalized treatment plans within two weeks, showcasing the practical effectiveness and potential clinical value of this advanced care.
- Strategic Significance: This collaboration enhances NHS's genomic testing infrastructure and introduces additional indications for future cancer screening programs, marking a pivotal moment for the scalable application of liquid biopsy in the UK and promoting accessibility in precision oncology.
See More
SOPHiA GENETICS Partners with Synnovis for Liquid Biopsy Testing in the UK
- Launch of Liquid Biopsy Testing: SOPHiA GENETICS has partnered with Synnovis to introduce the MSK-ACCESS® liquid biopsy test as part of NHS's 'blood test-first' initiative, aiming to serve approximately 7,000 lung and breast cancer patients annually.
- Accelerated Treatment Plans: This test detects actionable genomic alterations from a single blood draw, enabling cancer patients to receive targeted therapy up to two weeks earlier, thereby reducing the need for invasive treatments like chemotherapy and enhancing patient care.
- Real-World Impact: Following a successful pilot, Synnovis is currently supporting around 400 patients per month with ctDNA liquid biopsy testing, demonstrating the effectiveness of this technology in real-world healthcare settings and facilitating rapid personalized treatment plans for patients.
- Strategic Implications: This collaboration not only showcases SOPHiA GENETICS' AI-driven analytical capabilities but also provides NHS with a scalable liquid biopsy solution, marking a significant advancement in the widespread application of precision oncology in the UK, which is expected to greatly improve cancer treatment outcomes.
See More
SOPHiA Genetics Reports Q1 2025 Earnings Results
- Earnings Highlights: SOPHiA Genetics reported a Q1 2025 GAAP EPS of -$0.27, indicating a loss; however, revenue increased to $21.7 million, reflecting a 21.9% year-over-year growth, showcasing the company's ongoing potential in the genomics sector.
- Guidance Reaffirmation: The company reaffirmed its FY 2025 revenue guidance, projecting revenues between $92 million and $94 million, representing approximately 20% to 22% year-over-year growth, indicating strong confidence in future performance and positive market demand.
- Market Performance: Despite the reported loss, SOPHiA Genetics' revenue growth highlights its competitiveness in the genomics market, particularly as precision medicine and personalized treatment gain traction, potentially attracting more investor interest.
- Strategic Outlook: The company continues to invest in R&D and market expansion, aiming to enhance market share through innovative technologies and product offerings, thereby achieving sustainable growth and solidifying its leadership position in the industry.
See More
SOPHiA GENETICS Reports Strong Q1 Results with 22% Revenue Growth
- Significant Revenue Growth: SOPHiA GENETICS achieved a 22% year-over-year revenue growth in Q1 2026, reaching $21.688 million, reflecting strong market demand for its precision medicine capabilities, particularly as U.S. hospitals and laboratories increasingly seek AI-driven solutions.
- Record Genomic Analyses: The company completed 108,000 genomic analyses in the first quarter, setting a new record that indicates the broad application of its platform and the continued expansion of its customer base, further solidifying its market position in new applications like Liquid Biopsy and BioPharma partnerships.
- Strong Future Growth Momentum: CEO Jurgi Camblong highlighted that with the launch of new applications and expansion in the U.S. market, the business momentum remains robust, which will serve as a major catalyst for future growth and enhance the company's operational leverage.
- Transparency in Non-IFRS Reporting: The company emphasizes the use of non-IFRS measures in its financial reporting to provide investors with a clearer understanding of its operational performance, acknowledging the limitations of these metrics while still offering valuable insights into the company's future financial health.
See More
SOPHiA GENETICS Partners with Mount Sinai to Advance Cancer Research
- Collaboration Enhances Cancer Research: SOPHiA GENETICS announced a partnership with Mount Sinai Health System to adopt the AI-driven SOPHiA DDM™ platform, aimed at advancing cancer research and genomic testing capabilities, supporting care for over 4,000 oncology patients annually.
- Efficiency Optimization through Technology Integration: Mount Sinai's Molecular Pathology team will leverage SOPHiA DDM™ to enhance next-generation sequencing capabilities for blood cancers and solid tumors, significantly reducing manual interpretation time by consolidating critical steps in the analysis pipeline, thereby improving operational efficiency.
- Global Network Expansion: Mount Sinai joins a network of over 990 global institutions utilizing SOPHiA DDM™ to accelerate precision medicine, reflecting SOPHiA GENETICS' mission to democratize data-driven medicine and improve patient outcomes worldwide.
- Commitment to Scientific Innovation: The Director of Molecular Oncology Pathology at Mount Sinai stated that this collaboration reinforces the hospital's commitment to scientific innovation by integrating powerful digital tools into workflows, supporting high-quality, data-driven cancer care, and enhancing testing turnaround times to improve patient care quality.
See More
SOPHiA GENETICS (SOPH) Q4 2025 Earnings Transcript
See More
